Literature DB >> 1127135

Naproxen metabolism in man.

E J Segre.   

Abstract

In summary, naproxen is an acidic, highly albumin-bound drug. After oral administration, it is promptly and fully absorbed. The mean half-life of the drug in man is 13 hours, close to ideal for twice-daily administration. The only metabolite detected in man is the 6-desmethyl compound. Both it and naproxen itself are excreted in the urine, primarily as conjugates. The kinetics of naproxen binding to serum albumin tend to limit attainable plasma levels. They increase little if the dose is increased beyond 500 mg twice daily, since greater concentrations are rapidly cleared. Albumin binding and competitive displacement are also responsible for potential interactions of naproxen with drugs such as warfarin, sulfonylureas, and aspirin. Experience thus far does not indicate that any of the potential interactions are clinically meaningful.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1127135     DOI: 10.1002/j.1552-4604.1975.tb01458.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

1.  Sulphation of o-desmethylnaproxen and related compounds by human cytosolic sulfotransferases.

Authors:  Charles N Falany; Peter Ström; Stellan Swedmark
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

2.  Lack of effect of a single-dose of sulglicotide on the bioavailability of diclofenac.

Authors:  M De Bernardi di Valserra; F Feletti; F Bertè; M Nazzari; A Cenedese; U Cornelli
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis.

Authors:  F Van Gerwen; J K Van der Korst; F W Gribnau
Journal:  Ann Rheum Dis       Date:  1978-02       Impact factor: 19.103

4.  Pharmacokinetics of naproxen in subjects with normal and impaired renal function.

Authors:  M Anttila; M Haataja; A Kasanen
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

5.  Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-02-28       Impact factor: 3.922

6.  Effects of the human SULT1A1 polymorphisms on the sulfation of acetaminophen,O-desmethylnaproxen, and tapentadol.

Authors:  Mohammed I Rasool; Ahsan F Bairam; Saud A Gohal; Amal A El Daibani; Fatemah A Alherz; Maryam S Abunnaja; Eid S Alatwi; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  Pharmacol Rep       Date:  2018-12-10       Impact factor: 3.024

Review 7.  Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-10       Impact factor: 9.546

8.  Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation.

Authors:  F A van den Ouweland; M J Franssen; L B van de Putte; Y Tan; C A van Ginneken; F W Gribnau
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.